Clinical Trial Update: Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating a neprilysin inhibitor to reduce myocardial fibrosis in heart failure with preserved ejection fraction; currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Myocardial Fibrosis

Drugs mentioned

• Unspecified neprilysin inhibitor (neprilysin inhibitor)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | Phase 4 | Status: NOT_YET_RECRUITING